Understanding Chemoimmunotherapy for Metastatic Triple-Negative Breast Cancer
Decoding the Heterogeneity in Chemo-Immunomodulation to Unlock the Potential of Chemoimmunotherapy in Metastatic Triple-Negative Breast Cancer
This work aims to find the best chemotherapy combinations to improve immune treatments for people with metastatic triple-negative breast cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-11168960 on NIH RePORTER |
What this research studies
Metastatic triple-negative breast cancer is a very aggressive type of cancer with limited treatment options. While current immune treatments combined with chemotherapy have shown some promise, they don't work as well as they could for this specific cancer. This project seeks to understand why these treatments are not always effective and to identify which chemotherapy drugs work best with immune therapies for each patient. By doing so, we hope to make these life-extending treatments more successful for you.
Who could benefit from this research
Good fit: This research is relevant for patients diagnosed with metastatic triple-negative breast cancer, particularly those who may be candidates for chemoimmunotherapy.
Not a fit: Patients with other types of breast cancer or those not eligible for chemoimmunotherapy may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to more effective and personalized chemoimmunotherapy strategies, improving outcomes for patients with metastatic triple-negative breast cancer.
How similar studies have performed: While chemoimmunotherapy has shown significant success in other solid tumors, its efficacy in metastatic triple-negative breast cancer is currently limited, indicating a need for optimization.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Gbadamosi, Mohammed Olusoji — University of Florida
- Study coordinator: Gbadamosi, Mohammed Olusoji
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.